Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

16.27USD
19 Oct 2018
Change (% chg)

$-0.25 (-1.51%)
Prev Close
$16.52
Open
$16.62
Day's High
$16.91
Day's Low
$16.18
Volume
1,875,305
Avg. Vol
1,269,347
52-wk High
$32.20
52-wk Low
$15.49

Latest Key Developments (Source: Significant Developments)

Exelixis' Partner Ipsen Announces Health Canada's Approval Of Cabometyx Tablets
Wednesday, 19 Sep 2018 07:32am EDT 

Sept 19 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER IPSEN ANNOUNCES HEALTH CANADA’S APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED ADVANCED RENAL CELL CARCINOMA.EXELIXIS INC - UNDER TERMS OF COLLABORATION AGREEMENT WITH IPSEN, CO WILL RECEIVE A MILESTONE PAYMENT OF $5 MILLION FOR HEALTH CANADA APPROVAL.EXELIXIS INC - PAYMENT WILL BE MADE BY IPSEN WITHIN NEXT 70 DAYS.EXELIXIS - UNDER TERMS OF AGREEMENT WITH IPSEN, CO WILL RECEIVE A MILESTONE PAYMENT OF $5 MILLION FOR HEALTH CANADA APPROVAL.  Full Article

Exelixis Says Ipsen received validation of the application for variation to the Cabometyx
Wednesday, 28 Mar 2018 01:05am EDT 

March 28 (Reuters) - Exelixis Inc ::EXELIXIS’ PARTNER IPSEN ANNOUNCES EMA VALIDATION OF THE APPLICATION FOR A NEW INDICATION FOR CABOMETYX® (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA.‍FILING IS BASED ON RESULTS OF GLOBAL PIVOTAL PHASE 3 CELESTIAL TRIAL, WHICH MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS)​.‍CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS COMPARED WITH PLACEBO​.  Full Article

Daiichi Sankyo's Regulatory Submission Triggers $20 Mln Milestone Payment To Exelixis​
Monday, 26 Feb 2018 08:00pm EST 

Feb 26 (Reuters) - Exelixis Inc ::CO ‍ANNOUNCES COLLABORATOR DAIICHI SANKYO'S SUBMISSION OF REGULATORY FILING FOR ESAXERENONE (CS-3150) IN JAPAN​.‍FILING TRIGGERS $20 MILLION MILESTONE PAYMENT TO EXELIXIS​.  Full Article

Exelixis Posts Q4 Earnings Per Share $0.12
Monday, 26 Feb 2018 04:05pm EST 

Feb 26 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 EARNINGS PER SHARE $0.12.Q4 REVENUE $120.1 MILLION VERSUS $77.6 MILLION.  Full Article

Exelixis Announces Results From A Phase 2 Trial Of Cabozantinib In The First-Line Treatment Of Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Tuesday, 13 Feb 2018 04:05pm EST 

Feb 13 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES RESULTS FROM A PHASE 2 INVESTIGATOR-SPONSORED TRIAL OF CABOZANTINIB IN THE FIRST-LINE TREATMENT OF METASTATIC RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CARCINOMA.EXELIXIS INC - ‍EXELIXIS PLANS TO INITIATE A PIVOTAL PHASE 3 TRIAL LATER THIS YEAR​.EXELIXIS INC - ‍54 PERCENT OBJECTIVE RESPONSE RATE AND 43 PERCENT STABLE DISEASE OBSERVED AMONG 35 EVALUABLE PATIENTS​.  Full Article

Exelixis Enters Into Exclusive Collaboration And License Agreement With Stemsynergy Therapeutics
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Exelixis Inc ::EXELIXIS - ENTERED INTO EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT WITH STEMSYNERGY THERAPEUTICS.EXELIXIS INC- AGREEMENT FOR DISCOVERY AND DEVELOPMENT OF NOVEL ONCOLOGY COMPOUNDS TARGETING CASEIN KINASE 1 ALPHA.EXELIXIS INC- WILL PAY STEMSYNERGY UPFRONT PAYMENT OF $3 MILLION AND UP TO $3.5 MILLION IN INITIAL RESEARCH AND DEVELOPMENT FUNDING.EXELIXIS INC- CO WILL BE SOLELY RESPONSIBLE FOR COMMERCIALIZATION OF PRODUCTS THAT ARISE FROM COLLABORATION.  Full Article

Exelixis Announces Amendment To Protocol For Phase 1B Trial Of Cabozantinib In Combination With Atezolizumab
Thursday, 4 Jan 2018 08:00am EST 

Jan 4 (Reuters) - Exelixis Inc ::EXELIXIS INC - AMENDMENT TO PROTOCOL FOR PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB.EXELIXIS INC - AMENDMENT ADDS FOUR NEW EXPANSION COHORTS TO PHASE 1B TRIAL, WHICH WILL NOW INCLUDE PATIENTS WITH NSCLC AND CRPC.  Full Article

FDA Says Approved Exelixis' sNDA For Patients With Previously Untreated Advanced RCC
Tuesday, 19 Dec 2017 03:44pm EST 

Dec 19 (Reuters) - FDA::FDA SAYS APPROVED EXELIXIS' SNDA FOR PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RCC.FDA SAYS GRANTED EXELIXIS' CURRENTLY APPROVED TREATMENT OPTION BROADENED LABEL THAT NOW INCLUDES ALL ELIGIBLE PATIENTS WITH ADVANCED RCC.  Full Article

Exelixis Announces FDA Approval Of Cabometyx Tablets For Previously Untreated Advanced Renal Cell Carcinoma
Tuesday, 19 Dec 2017 02:54pm EST 

Dec 19 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA.EXELIXIS INC - APPROVAL OF CABOMETYX TABLETS EXPANDS INDICATION AND COMES WELL IN ADVANCE OF PDUFA DATE OF FEBRUARY 15, 2018.  Full Article

Exelixis reports Q3 earnings per share $0.26
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Exelixis Inc :Exelixis announces third quarter 2017 financial results and provides corporate update.Q3 earnings per share $0.26.Q3 revenue $152.5 million versus $62.2 million.Q3 revenue view $104.9 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.08 -- Thomson Reuters I/B/E/S.Exelixis Inc - ‍is updating its guidance that total costs and operating expenses for full year will be between $285 million and $295 million​.  Full Article

BRIEF-Exelixis Appoints Andrew Peters To Newly Created Position Of Vice President, Strategy

* EXELIXIS APPOINTS ANDREW R. PETERS TO NEWLY CREATED POSITION OF VICE PRESIDENT, STRATEGY Source text for Eikon: Further company coverage: